Allopregnanolone
|
Basic information |
| Metabolite name | Allopregnanolone |
 | HMDB0001449 |
 |
C13712 |
 |
92786 |
| Synonyms | Alloprognanolone |
| No. of studies | 7 |
|
Basic information |
| Metabolite name | Allopregnanolone |
| HMDB0001449 |
|
C13712 |
|
92786 |
| Synonyms | Alloprognanolone |
| No. of studies | 7 |
|
Relationship between Allopregnanolone and depression (count: 7) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1131 | Type1 | CUS group vs. control group | Basolateral amygdala | C57BL/6J mouse | Down |
| Study M152 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M152 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M152 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M152 | Type2 | CUMS + XYS group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M174 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M446 | Type1 | depressed group vs. control group | Cerebrospinal fluid | Human | Down |
| Study M446 | Type2 | fluoxetine-treated depressed group post-treatment vs. baseline | Cerebrospinal fluid | Human | Up |
| Study M532 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M599 | Type1 | PND group vs. control group | Plasma | Human | Up |
| Study M712 | Type1 | depression group vs. control group | Intestine | Cynomolgus monkey | Up |